After the end of the experimentation the end users involved showed an improvement on MPI score (5%); ADL (3.5%); IADL (2.8%); MNA (13.3%); Exthon-Smith scale (2.7%); MMSE (1.45); HAM-D score (24.55%); GDS score (25.67%), NPI score (13.22%) and CGB (11.78%). No improvements were showed on CIRS and in the number of drugs taken.
Also they showed an improvement of 47.89% on the Q-LES-Q score. The clear limitation of this data is bounded to the sample size that consists of two installed prototype so a generalization of this data are not possible. Although these data are promising and further randomized multicenter study could confirm these results.